Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Overview of Elite Pharmaceuticals Inc.
Elite Pharmaceuticals Inc. (ELTP) is a specialty pharmaceutical company renowned for developing, manufacturing, and distributing niche generic products. With a strategic focus on sustained and controlled release oral formulations, the company transforms life cycle management of off-patent drugs into innovative and high barrier-to-entry generic solutions. Utilizing state-of-the-art technology and stringent regulatory standards such as cGMP and DEA requirements, Elite positions its product lines within a competitive landscape while ensuring manufacturing excellence and quality assurance.
Core Business Areas and Product Innovation
At its core, Elite Pharmaceuticals specializes in controlled release drug products that address common challenges in drug delivery, particularly in chronic pain management and central nervous system disorders. The company’s streamlined process encompasses:
- Formulation Innovation: Engineering novel sustained release and immediate-release products to improve therapeutic outcomes.
- ANDA Lifecycle Management: Assisting partner companies in refining and life cycle managing off-patent drug products to extend market viability.
- Pipeline Development: Developing advanced generic formulations, including abuse-resistant opioids and other critical therapeutics, ensuring robust barriers to market entry for competitors.
Manufacturing Excellence and Regulatory Adherence
Elite Pharmaceuticals operates a cGMP and DEA registered facility in Northvale, NJ, underscoring its commitment to quality and compliance. This facility is equipped for research and development, as well as full-scale manufacturing, enabling the company to consistently meet rigorous FDA standards. The company has secured multiple ANDA approvals, reinforcing its capability to navigate complex regulatory environments and deliver reliable generic drug products across multiple therapeutic classes.
Strategic Partnerships and Market Position
The company distinguishes itself through strategic alliances with established pharmaceutical marketing and distribution partners. Such collaborations facilitate expanded market access and efficient product lifecycle management. For instance, partnerships with firms like TAGI Pharma and ECR Pharmaceuticals enhance Elite's portfolio and operational reach, while licensing arrangements support broader product dissemination under the Elite Laboratories label.
Competitive Landscape and Value Proposition
In a highly competitive generic pharmaceuticals sector, Elite Pharmaceuticals maintains its relevance by focusing on high-quality, controlled-release oral dosage forms that are considerably challenging for competitors to replicate. By emphasizing innovation in formulation, regulatory expertise, and strategic market positioning, the company provides an enduring value proposition. Its targeted product strategy, ranging from generic methotrexate sodium tablets to controlled-release opioid formulations for chronic pain, exemplifies deep industry insight and a commitment to addressing unmet therapeutic needs.
Conclusion
Elite Pharmaceuticals Inc. stands as a nuanced and credible entity within the specialty pharmaceuticals community. Its robust R&D capabilities, state-of-the-art manufacturing facility, and strategic collaborations collectively underscore its expertise in developing niche generic products. Whether addressing the complexities of controlled release formulations or achieving regulatory milestones, Elite continues to build a comprehensive portfolio designed to excel in both immediate and long-term market demands.
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic methotrexate sodium 2.5 mg tablets. This medication is a dihydrofolate reductase inhibitor used to treat various conditions in adults and children, including acute lymphoblastic leukemia, rheumatoid arthritis, and severe psoriasis.
The product is marketed under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately $63 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment within the pharmaceutical industry.
Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q1 FY2025 ended June 30, 2024. Highlights include:
- Consolidated revenues of $18.8 million, up 109% year-over-year
- Operating profits of $3.9 million, increased 144% year-over-year
- Net income attributable to common shareholders of $0.6 million
The significant growth in operating profits was primarily due to higher sales of Elite label products. The company will host a conference call on August 15, 2024, at 11:30 AM EDT to discuss the results and provide business updates. Stockholders can submit questions in advance to dianne@elitepharma.com by August 14, 2024, 7:00 PM EDT.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, has announced its upcoming financial release and conference call schedule. The company will release its first quarter financial results for fiscal year 2025 on August 14, 2024. Following this, Elite's management will host a live conference call on August 15, 2024, at 11:30 AM EDT to discuss the financial and operating results, as well as provide a general business update.
Stockholders are encouraged to submit questions to the company prior to the call. The dial-in numbers for the conference are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with the conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals announced its fiscal year-end results for March 31, 2024, showing a significant performance boost. The company reported consolidated revenues of $56.6 million, marking a 65% increase from the previous fiscal year. Operating profits surged by 192% to $10.8 million, largely due to the launch of the Elite label product line. Net income attributable to common shareholders stood at $20.1 million. Elite will host a conference call on July 2, 2024, at 11:30 AM EDT to discuss these results and recent business developments. Stockholders are encouraged to submit financial questions in advance.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, announced they will release their fiscal year 2024 financial results on July 1, 2024. To discuss these results, Elite will host a live conference call on July 2, 2024, at 11:30 AM EDT. Shareholders are encouraged to submit their questions by June 28, 2024, for general queries, and by July 1, 2024, for financial queries. The conference call will provide an overview of financial and operating results along with a business update. The call can be accessed via specific dial-in numbers for domestic and international participants.
Elite Pharmaceuticals announced FDA approval for its generic Methotrexate Sodium 2.5 mg tablets. This approval relates to an Abbreviated New Drug Application (ANDA) and adds to Elite's portfolio of niche generic products. The generic Methotrexate, classified as an antimetabolite, will be marketed under Elite Laboratories. According to IQVIA, the generic market for Methotrexate had annual sales of $64.3 million for the twelve months ending March 2024. Elite Pharmaceuticals focuses on developing, manufacturing, and distributing immediate-release and controlled-release solid oral dose products, operating from a cGMP and DEA registered facility in Northvale, NJ.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
What is the core business of Elite Pharmaceuticals Inc.?
What are the primary product areas served by the company?
How does Elite Pharmaceuticals manage its product lifecycle?
What role does regulatory compliance play in the company’s operations?
How does Elite Pharmaceuticals differentiate itself from competitors?
What strategic partnerships support Elite Pharmaceuticals’ business model?
Where is Elite Pharmaceuticals headquartered and how does this benefit their operations?
How does the company contribute to addressing challenges in pain management?
